Literature DB >> 8557859

Alopecia areata in Korea (1982-1994).

B I Ro1.   

Abstract

I clinically studied 905 patients with alopecia areata (AA) who visited the Department of Dermatology, College of Medicine, Chung Ang University, from January of 1982 to February of 1994. The purpose of the study was to evaluate the clinical manifestations and compare the effects of treatment with intralesional injection of triamcinolone acetonide suspension and immunotherapy with dinitrochlorobenzene (DNCB) or diphenylcyclopropenone (DPCP). The results were as follows: 1) The incidence of AA among all out-patients (59,970) was 1.5% (905 cases), and the ratio of males to females was 1.3:1 (512:393). 2) The age distribution showed high incidences in the third (41.8%) and fourth decades (20.0%). 3) The family history was contributory in 104 cases (11.5%). 4) The relapse rate was 17.5% (158 cases). 5) Almost half of the patients had a solitary lesion (408 cases, 46.7%). 6) The most common site of predilection was the occipital region of the scalp in both male and female patients. 7) Associated diseases were seborrheic dermatitis, atopic dermatitis, hepatitis, hypertension, open heart surgery, thyroid disease, pulmonary disease, and vitiligo in order of frequency. 8) The effect of treatment on the patients who had bald patches less than 50 cm2 was not significantly statistically different between intralesional injection of triamcinolone acetonide and immunotherapy with DNCB or DPCP. 9) In cases with bald areas more than 50 cm2, including alopecia totalis and universalis, DNCB or DPCP immunotherapy showed better therapeutic effects than did intralesional injection of triamcinolone acetonide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557859     DOI: 10.1111/j.1346-8138.1995.tb03936.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  8 in total

Review 1.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

2.  Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model.

Authors:  John P Sundberg; Kathleen A Silva; Weidong Zhang; Beth A Sundberg; Kathryn Edwards; Lloyd E King; Robert L Davis; Steven Black
Journal:  Vet Dermatol       Date:  2009-01-17       Impact factor: 1.589

3.  The Immunological Association between Alopecia Areata and Respiratory Diseases: A Systematic Review.

Authors:  Calvin T Sung; Franchesca D Choi; Margit Juhász; Natasha Atanaskova Mesinkovska
Journal:  Skin Appendage Disord       Date:  2019-02-26

4.  Development of autoimmune hair loss disease alopecia areata is associated with cardiac dysfunction in C3H/HeJ mice.

Authors:  Eddy Wang; Katy Chong; Mei Yu; Noushin Akhoundsadegh; David J Granville; Jerry Shapiro; Kevin J McElwee
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

5.  Prevalence and Clinical Characteristics of Alopecia Areata at a Tertiary Care Center in Saudi Arabia.

Authors:  Aysha A Alshahrani; Rawan Al-Tuwaijri; Zainah A Abuoliat; Mesnad Alyabsi; Mohammed I AlJasser; Rayan Alkhodair
Journal:  Dermatol Res Pract       Date:  2020-03-13

6.  Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis.

Authors:  Aditya K Gupta; Jessie L Carviel; Kelly A Foley; Neil H Shear; Bianca Maria Piraccini; Vincent Piguet; Antonella Tosti
Journal:  Skin Appendage Disord       Date:  2019-08-29

7.  Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study.

Authors:  Tugba Kevser Uzuncakmak; Burhan Engin; Server Serdaroglu; Yalcin Tuzun
Journal:  Skin Appendage Disord       Date:  2020-10-28

8.  Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Authors:  Zekayi Kutlubay; Ayşegül Sevim; Övgü Aydın; Suphi Vehid; Server Serdaroğlu
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.